Greenwich LifeSciences Stock (NASDAQ:GLSI)

Revenue Ownership Financials Chart

Previous Close

$12.77

52W Range

$8.00 - $21.44

50D Avg

$13.93

200D Avg

$14.42

Market Cap

$168.91M

Avg Vol (3M)

$30.17K

Beta

3.32

Div Yield

-

GLSI Company Profile

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

3

IPO Date

Sep 25, 2020

Website

GLSI Performance

GLSI Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-9.33M	$-8.04M	$-4.60M
Net Income	$-8.89M	$-7.61M	$-4.54M
EBITDA	$-9.33M	$-8.04M	$-4.59M
Basic EPS	$-0.69	$-0.59	$-0.35
Diluted EPS	$-0.69	$-0.59	$-0.35

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
XFOR	X4 Pharmaceuticals, Inc.
AVXL	Anavex Life Sciences Corp.
NXTC	NextCure, Inc.
RVPH	Reviva Pharmaceuticals Holdings, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
VRPX	Virpax Pharmaceuticals, Inc.
PDSB	PDS Biotechnology Corporation
ACXP	Acurx Pharmaceuticals, Inc.
TERN	Terns Pharmaceuticals, Inc.
INZY	Inozyme Pharma, Inc.
IMMP	Immutep Limited
EYEN	Eyenovia, Inc.
MNOV	MediciNova, Inc.
ABOS	Acumen Pharmaceuticals, Inc.
ENTX	Entera Bio Ltd.
AMLX	Amylyx Pharmaceuticals, Inc.